Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

CGEM

Cullinan Therapeutics Inc

Apr 19 • 02:58PM ET

15.49

Dollar change -2.56
Percentage change -14.20	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWN IBB SCHA DFAT FDM VTWO DFAC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.70	Insider Own	38.80%	Shs Outstand	42.90M	Perf Week	-7.05%
Market Cap	667.37M	Forward P/E	-	EPS next Y	-3.03	Insider Trans	-0.80%	Shs Float	26.36M	Perf Month	-0.23%
Income	-153.16M	PEG	-	EPS next Q	-0.97	Inst Own	56.13%	Short Float	5.45%	Perf Quarter	34.62%
Sales	0.00M	P/S	-	EPS this Y	11.25%	Inst Trans	-1.51%	Short Ratio	2.90	Perf Half Y	71.40%
Book/sh	10.58	P/B	1.47	EPS next Y	7.37%	ROA	-29.28%	Short Interest	1.44M	Perf Year	48.28%
Cash/sh	10.84	P/C	1.43	EPS next 5Y	-	ROE	-30.98%	52W Range	7.64 - 20.62	Perf YTD	52.06%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-62.42%	ROI	-33.60%	52W High	-24.85%	Beta	0.27
Dividend TTM	-	Quick Ratio	17.07	Sales past 5Y	-20.00%	Gross Margin	-	52W Low	102.81%	ATR (14)	1.40
Dividend Ex-Date	-	Current Ratio	17.07	EPS Y/Y TTM	-248.40%	Oper. Margin	0.00%	RSI (14)	40.07	Volatility	11.29% 6.48%
Employees	85	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	28.00
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	4.99%	Payout	-	Rel Volume	1.74	Prev Close	18.06
Sales Surprise	-	EPS Surprise	43.83%	Sales Q/Q	-	Earnings	Mar 14 BMO	Avg Volume	495.89K	Price	15.49
SMA20	-9.35%	SMA50	-10.48%	SMA200	29.85%	Trades		Volume	731,795	Change	-14.20%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-15-24	Initiated	William Blair	Outperform
Feb-15-24	Initiated	Wedbush	Outperform	$30
Jun-15-23	Initiated	TD Cowen	Outperform
Nov-21-22	Initiated	BTIG Research	Buy	$20
Apr-27-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$40
Feb-02-21	Initiated	SVB Leerink	Outperform	$52
Feb-02-21	Initiated	Morgan Stanley	Equal-Weight	$38
Feb-02-21	Initiated	Evercore ISI	Outperform	$55
Feb-01-21	Initiated	H.C. Wainwright	Buy	$47

Apr-16-24 03:32PM	Cullinan Shifts Focus From Oncology To Autoimmune Disorders, Raises $280M Via Equity (Benzinga)
07:00AM	Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases (GlobeNewswire)
06:59AM	Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement (GlobeNewswire)
04:48AM	Cullinan changes name, pivots to autoimmune disease (BioPharma Dive)
Mar-16-24 05:31AM	Cullinan Oncology Inc (CGEM) Reports Fourth Quarter and Full Year 2023 Financial Results (GuruFocus.com)
12:53PM	Loading…
Mar-14-24 12:53PM	CGEM Stock Earnings: Cullinan Oncology Beats EPS for Q4 2023 (InvestorPlace)
07:00AM	Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Mar-01-24 07:00AM	Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma (GlobeNewswire)
Feb-27-24 08:00AM	Cullinan Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-21-24 09:21AM	13 Best Booming Stocks to Buy Right Now (Insider Monkey)
Feb-02-24 11:01PM	Chief Business Officer Corrine Savill Sells 40,000 Shares of Cullinan Oncology Inc (GuruFocus.com)
Jan-30-24 11:01PM	Chief Business Officer Corrine Savill Sells 40,000 Shares of Cullinan Oncology Inc (GuruFocus.com)
Jan-24-24 07:02PM	Insider Sell: Cullinan Oncology Inc's Chief Business Officer Corrine Savill Sold 40,000 Shares (GuruFocus.com)
Dec-18-23 04:53PM	Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +10.80%
Dec-14-23 04:30PM	Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines (GlobeNewswire)
07:00AM	Loading…
Nov-08-23 07:00AM	Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-03-23 12:01PM	Cullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023 (GlobeNewswire) +5.53%
Oct-30-23 08:00AM	Cullinan Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Sep-06-23 08:00AM	Cullinan Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-10-23 07:00AM	Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-09-23 07:00AM	Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-978, a Novel CD19xCD3 T cell Engager, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (GlobeNewswire)
Aug-03-23 04:15PM	REZILIENT3 Global First-Line Trial of Zipalertinib Launched in Patients With Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations (PR Newswire)
Jul-31-23 08:00AM	Cullinan Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jun-09-23 04:07PM	Why Shares of Cullinan Oncology Jumped This Week (Motley Fool)
May-25-23 05:00PM	Cullinan Oncology to Present First Monotherapy Clinical Data for CLN-619, a Novel Anti-MICA/B Antibody, at ASCO 2023 (GlobeNewswire)
May-11-23 04:01PM	Cullinan Oncology Provides Corporate Update and Reports First Quarter 2023 Financial Results (GlobeNewswire)
Apr-26-23 10:08AM	Cullinan Oncology to Present First Clinical Data Evaluating Novel Anti-MICA/B Antibody, CLN-619, in Patients with Advanced Solid Tumors at ASCO 2023 (GlobeNewswire)
Apr-20-23 07:00AM	Cullinan Oncology to Participate in Stifels 2023 Targeted Oncology Days (GlobeNewswire)
Mar-29-23 10:13AM	12 Cheap Healthcare Stocks to Buy in 2023 (Insider Monkey)
Mar-27-23 07:00AM	Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-617, a Novel Fusion Protein Harnessing IL-2 and IL-12 Cytokines (GlobeNewswire)
04:35PM	Loading…
Mar-14-23 04:35PM	Cullinan Oncology to Present New Preclinical Data for CLN-619 and CLN-617 at the 2023 American Association for Cancer Research Annual Meeting (GlobeNewswire)
Mar-09-23 07:00AM	Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Feb-27-23 08:00AM	Cullinan Oncology to Participate in Cowens 43rd Annual Health Care Conference (GlobeNewswire)
Feb-13-23 07:00PM	Cullinan Oncology Licenses U.S. Rights to the First Clinical-Stage B7H4 x 4-1BB Bispecific Immune Activator from Harbour BioMed (GlobeNewswire)
Feb-02-23 04:01PM	Cullinan Oncology to Participate in the Guggenheim 5th Annual Oncology Conference and the SVB Securities Global Biopharma Conference (GlobeNewswire)
Feb-01-23 04:42PM	Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-24-23 08:00AM	Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-978, a Novel T-Cell Engager for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (GlobeNewswire) +5.53%
Jan-23-23 11:07AM	12 Most Undervalued Pharma Stocks To Buy According To Hedge Funds (Insider Monkey)
Jan-03-23 05:13PM	Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-28-22 10:31PM	11 Cheap Value Stocks to Buy According to Seth Klarman (Insider Monkey)
Dec-02-22 05:00PM	Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-14-22 07:00AM	Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2022 Financial Results (GlobeNewswire)
Nov-02-22 08:00AM	Cullinan Oncology Announces the Appointment of David P. Ryan, M.D. to its Board of Directors (GlobeNewswire)
Nov-01-22 05:23PM	Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
07:00AM	Cullinan Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-25-22 07:00AM	Cullinan Oncology Significantly Increases Ownership Stake in its MICA Subsidiary which Holds Worldwide Rights to Clinical-Stage Novel Monoclonal Antibody CLN-619 (GlobeNewswire) +6.03%
Oct-03-22 04:50PM	Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-07-22 08:00AM	Cullinan Oncology to Participate in the HC Wainwright Global Investment Conference and the Morgan Stanley Healthcare Conference (GlobeNewswire) +5.36%
Sep-01-22 05:27PM	Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-15-22 04:57PM	Cullinan Oncology Announces Appointment of Jacquelyn Sumer as Chief Legal Officer (GlobeNewswire)
Aug-10-22 07:00AM	Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2022 Financial Results (GlobeNewswire)
Aug-01-22 04:55PM	Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Cullinan Oncology to Participate in BTIG Biotechnology Conference and Canaccord Growth Conference (GlobeNewswire)
Jul-29-22 05:00AM	Why are Massachusetts CEOs paid so much money? Here's a primer (American City Business Journals)
05:00AM	Best bang for the buck: Which CEOs are a bargain for shareholders? (American City Business Journals)
Jul-05-22 04:01PM	Cullinan Oncology to Participate in William Blair Biotech Focus Conference (GlobeNewswire)
Jul-01-22 04:37PM	Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-23-22 08:00AM	Cullinan Oncology and Taiho Pharmaceutical Complete Agreement for Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417 (GlobeNewswire)
Jun-01-22 05:00PM	Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.08%
May-31-22 08:00AM	Cullinan Oncology to Present Updated Data Demonstrating the Therapeutic Potential of CLN-081 in Patients with EGFR Exon 20 Insertion Mutation Positive Non-Small Cell Lung Cancer at the 2022 ASCO Annual Meeting (GlobeNewswire) -6.88%
May-26-22 08:45AM	Cullinan Oncology to Host Analyst and Investor Briefing at 2022 ASCO Annual Meeting (GlobeNewswire)
May-19-22 08:00AM	Cullinan Oncology to Present at H.C. Wainwright Global Investment Conference (GlobeNewswire) -5.01%
May-16-22 06:45AM	Cullinan Oncology Provides Corporate Update and Reports First Quarter 2022 Financial Results (GlobeNewswire)
May-12-22 11:18AM	Why Are Cullinan Oncology Shares Rising Today? (Benzinga) +23.12%
02:00AM	Cullinan Oncology and Taiho Pharmaceutical Announce Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417 and Taihos Acquisition of Cullinan Pearl (GlobeNewswire)
May-08-22 09:23AM	Companies Like Cullinan Oncology (NASDAQ:CGEM) Are In A Position To Invest In Growth (Simply Wall St.)
May-02-22 05:00PM	Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.34%
Apr-27-22 10:00AM	Cullinan Oncology to Present Updated Data Highlighting the Therapeutic Potential of CLN-081 in Patients with EGFR Exon 20 Insertion Mutation Positive Non-Small Cell Lung Cancer at the 2022 ASCO Annual Meeting (GlobeNewswire)
Apr-05-22 08:00AM	Cullinan Oncology to Participate in Upcoming Virtual Healthcare Conferences (GlobeNewswire)
Apr-04-22 04:34PM	Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +9.55%
Mar-29-22 07:54AM	Cullinan Oncology Lead Cancer Program Shows Confirmed ORR Of 41% In Lung Cancer Setting (Benzinga)
Mar-28-22 04:01PM	Cullinan Oncology Announces Clinical and Regulatory Update for CLN-081 in NSCLC EGFR Exon 20 Patients (GlobeNewswire)
Mar-17-22 07:08AM	Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire)
07:00AM	Cullinan Oncology to Host CLN-081 Regulatory Update Webinar on March 28, 2022 (GlobeNewswire)
Mar-09-22 08:00AM	Cullinan Oncology to Present at the Barclays Global Healthcare Conference (GlobeNewswire) +8.91%
Mar-08-22 05:30PM	Cullinan Oncology to Present Data Demonstrating Breadth and Progress of Its Immuno-Oncology Portfolio at AACR 2022 (GlobeNewswire)
Feb-28-22 08:00AM	Cullinan Oncology Expands Leadership Team and Board of Directors with Appointments of Jeffrey Jones, M.D., MPH, MBA to Chief Medical Officer and Anne-Marie Martin Ph.D. to Board of Directors (GlobeNewswire)
Feb-12-22 06:50AM	Investors in Cullinan Oncology (NASDAQ:CGEM) have unfortunately lost 66% over the last year (Simply Wall St.)
Feb-07-22 06:30AM	Cullinan Oncology to Present at SVB Leerinks 11th Annual Global Healthcare Conference (GlobeNewswire) +6.52%
Jan-10-22 06:30AM	Cullinan Oncology Forms Strategic Collaboration Agreement with Mount Sinai to Advance Oral HPK1 Protein Degrader for Cancer Treatment (GlobeNewswire)
Jan-05-22 09:00AM	Cullinan Oncology to Present at Upcoming Virtual Investor Conferences (GlobeNewswire) -6.69%
Jan-04-22 07:34AM	Cullinan Oncology stock shoots higher after lung cancer treatment granted BTD by FDA (MarketWatch)
07:00AM	FDA Grants Breakthrough Therapy Designation for Cullinan Oncologys CLN-081 in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer (GlobeNewswire)
Dec-16-21 01:04PM	Cullinan Oncology Posts Updated Data for CLN-081 in NSCLC EGFR Exon 20 Patients (Benzinga)
06:30AM	Cullinan Oncology Announces Updated Phase 1/2a Data for CLN-081 in NSCLC EGFR Exon 20 Patients (GlobeNewswire)
Dec-13-21 07:00AM	Cullinan Oncology to Provide Clinical Update for CLN-081 in NSCLC EGFR Exon 20 Patients (GlobeNewswire)
Nov-22-21 12:37PM	Cullinan Oncology to Participate in the Evercore ISI 4th Annual HealthconX Conference (GlobeNewswire)
Nov-14-21 07:04AM	Cullinan Oncology, Inc. (NASDAQ:CGEM) insiders snagged a deal: Up US$35k on a US$4.3m investment (Simply Wall St.)
Nov-09-21 06:45AM	Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2021 Financial Results (GlobeNewswire)
Oct-29-21 11:47AM	Do Hedge Funds Love Cullinan Oncology, Inc. (CGEM)? (Insider Monkey)
Oct-18-21 07:00AM	Cullinan Oncology Appoints Nadim Ahmed as Chief Executive Officer (GlobeNewswire) -15.52%
Sep-08-21 04:01PM	Cullinan Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-16-21 06:44AM	We're Hopeful That Cullinan Oncology (NASDAQ:CGEM) Will Use Its Cash Wisely (Simply Wall St.)
Aug-10-21 06:30AM	Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2021 Financial Results (GlobeNewswire) +6.70%
Aug-05-21 04:05PM	Cullinan Oncology to Participate in the 41st Annual Canaccord Genuity Growth Conference (GlobeNewswire) +13.58%
Jul-19-21 07:56PM	Is Cullinan Oncology, Inc. (CGEM) A Good Stock To Buy? (Insider Monkey)
Jun-29-21 08:00AM	Cullinan Oncology Receives FDA Clearance of Investigational New Drug (IND) Application for CLN-619, a Novel MICA/B-targeted Antibody for the Treatment of Solid Tumors (GlobeNewswire)
Jun-07-21 10:57AM	Cullinan Gets FDA Investigational Clearance for Leukemia Drug (TheStreet.com)
09:26AM	Cullinan (CGEM) Rises on Promising Phase I Cancer Study Data (Zacks)
08:30AM	Cullinan Oncology Receives Investigational New Drug (IND) Clearance from the FDA for CLN-049, a FLT3 x CD3 Bispecific Antibody for the Treatment of Relapsed/Refractory AML (GlobeNewswire)

Cullinan Oncology, Inc. is a biopharmaceutical company engaged in developing oncology and immuno-oncology therapies. The company was founded by Patrick R. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Savill Corrine	Chief Business Officer	Feb 01 '24	Option Exercise	4.30	40,000	172,000	205,990	Feb 02 09:35 PM
Savill Corrine	Chief Business Officer	Feb 01 '24	Sale	16.18	40,000	647,200	165,990	Feb 02 09:35 PM
Savill Corrine	Chief Business Officer	Jan 29 '24	Option Exercise	4.30	40,000	172,000	205,990	Jan 30 07:00 PM
Savill Corrine	Chief Business Officer	Jan 29 '24	Sale	14.09	40,000	563,600	165,990	Jan 30 07:00 PM
Savill Corrine	Chief Business Officer	Jan 23 '24	Option Exercise	4.30	21,316	91,659	187,306	Jan 24 05:00 PM
Savill Corrine	Chief Business Officer	Jan 23 '24	Sale	12.46	21,316	265,597	165,990	Jan 24 05:00 PM
Savill Corrine	Chief Business Officer	Jan 22 '24	Option Exercise	4.30	14,559	62,604	184,674	Jan 24 05:00 PM
Savill Corrine	Chief Business Officer	Jan 22 '24	Sale	12.14	18,684	226,911	165,990	Jan 24 05:00 PM
AHMED NADIM	President and CEO	Dec 26 '23	Sale	9.24	4,272	39,473	111,550	Dec 27 06:30 PM
Trigilio Jeffrey	Chief Financial Officer	Dec 21 '23	Sale	8.50	1,920	16,320	83,919	Dec 22 05:30 PM
Jones Jeffrey Alan	Chief Medical Officer	Dec 21 '23	Sale	8.50	1,860	15,810	56,191	Dec 22 05:30 PM
SUMER JACQUELYN L	Chief Legal Officer	Dec 21 '23	Sale	8.50	1,400	11,900	44,133	Dec 22 05:30 PM
Michaelson Jennifer	Chief Scientific Officer	Dec 21 '23	Sale	8.50	1,145	9,732	87,582	Dec 22 05:30 PM
Trigilio Jeffrey	Chief Financial Officer	Dec 18 '23	Sale	8.22	398	3,272	85,839	Dec 20 06:00 PM
Jones Jeffrey Alan	Chief Medical Officer	Dec 18 '23	Sale	8.22	386	3,173	58,051	Dec 20 06:00 PM
SUMER JACQUELYN L	Chief Legal Officer	Dec 18 '23	Sale	8.22	290	2,384	45,533	Dec 20 06:00 PM
Michaelson Jennifer	Chief Scientific Officer	Dec 18 '23	Sale	8.22	238	1,956	88,727	Dec 20 06:00 PM
Trigilio Jeffrey	Chief Financial Officer	Dec 12 '23	Sale	7.81	1,926	15,042	86,237	Dec 13 08:00 PM
Michaelson Jennifer	Chief Scientific Officer	Dec 12 '23	Sale	7.81	1,068	8,341	88,965	Dec 13 08:00 PM
AHMED NADIM	President and CEO	Jun 28 '23	Sale	11.40	759	8,653	115,822	Jun 29 04:59 PM
Trigilio Jeffrey	Chief Financial Officer	Jun 20 '23	Sale	12.94	399	5,163	85,823	Jun 21 04:17 PM
Jones Jeffrey Alan	Chief Medical Officer	Jun 20 '23	Sale	12.94	387	5,008	58,437	Jun 21 04:17 PM
SUMER JACQUELYN L	Chief Legal Officer	Jun 20 '23	Sale	12.94	291	3,766	45,823	Jun 21 04:17 PM
Michaelson Jennifer	Chief Development Officer	Jun 20 '23	Sale	12.94	238	3,080	90,033	Jun 21 04:17 PM
Trigilio Jeffrey	Chief Financial Officer	Jun 12 '23	Sale	13.11	319	4,182	86,222	Jun 14 04:35 PM
Michaelson Jennifer	Chief Development Officer	Jun 12 '23	Sale	13.11	176	2,307	90,271	Jun 14 04:35 PM
Michaelson Jennifer	Chief Development Officer	Jun 07 '23	Option Exercise	4.30	100	430	90,547	Jun 08 05:10 PM
Michaelson Jennifer	Chief Development Officer	Jun 07 '23	Sale	12.40	100	1,240	90,447	Jun 08 05:10 PM
Michaelson Jennifer	Chief Development Officer	Jun 06 '23	Option Exercise	4.30	11,900	51,170	102,347	Jun 08 05:10 PM
Michaelson Jennifer	Chief Development Officer	Jun 06 '23	Sale	12.31	11,900	146,489	90,447	Jun 08 05:10 PM
AHMED NADIM	President and CEO	May 23 '23	Sale	9.15	707	6,469	116,581	May 24 04:36 PM
Trigilio Jeffrey	Chief Financial Officer	May 18 '23	Sale	8.76	399	3,495	86,541	May 19 04:44 PM
Jones Jeffrey Alan	Chief Medical Officer	May 18 '23	Sale	8.76	394	3,451	58,824	May 19 04:46 PM
SUMER JACQUELYN L	Chief Legal Officer	May 18 '23	Sale	8.76	291	2,549	46,114	May 19 04:45 PM
Michaelson Jennifer	Chief Development Officer	May 18 '23	Sale	8.76	239	2,094	90,447	May 19 04:51 PM
Trigilio Jeffrey	Chief Financial Officer	May 12 '23	Sale	8.78	347	3,047	86,940	May 16 05:28 PM
Michaelson Jennifer	Chief Development Officer	May 12 '23	Sale	8.78	193	1,695	90,686	May 16 05:36 PM
AHMED NADIM	President and CEO	Apr 25 '23	Sale	10.59	716	7,582	117,288	Apr 26 04:23 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CGEM

Cullinan Therapeutics Inc

Upgrade your FINVIZ experience